Last SFr.257.50 CHF
Change Today -0.50 / -0.19%
Volume 11.0K
RO On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 7:09 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RO) Snapshot

Open
SFr.257.50
Previous Close
SFr.258.00
Day High
SFr.258.75
Day Low
SFr.256.25
52 Week High
02/28/14 - SFr.272.75
52 Week Low
07/31/13 - SFr.227.70
Market Cap
225.2B
Average Volume 10 Days
18.3K
EPS TTM
SFr.13.16
Shares Outstanding
160.0M
EX-Date
03/6/14
P/E TM
19.6x
Dividend
SFr.7.80
Dividend Yield
3.03%
Current Stock Chart for ROCHE HOLDING AG-BR (RO)

roche holding ag-br (RO) Related Bloomberg News

View More Bloomberg News

roche holding ag-br (RO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RO) Key Developments

Roche Holding AG Revamps Research Operations, Cuts 1,000 US Jobs; Announces Executive Changes

Roche Holding AG announced that it was overhauling its research operations by closing the 80-year-old New Jersey facility where Valium was discovered, cutting 1,000 jobs and replacing its drug research chief. The company will also shutter its 127-acre Nutley, N.J.-based campus and move those activities to Germany and Switzerland, a consolidation aimed at curbing drug development costs. The sites in Switzerland and Germany are expected to add about 80 jobs. The moves will free up resources that it can invest in these promising clinical programs while also increasing overall efficiency. The move allows Roche to keep its research and drug development costs largely unchanged, despite an increase in clinical research projects in the last 18 months. Jean-Jacques Garaud, head of pharmaceutical research, will leave the company at the end of this week. He will be replaced by Mike Burgess, head of cancer drugs.

Roche Enters into Research Collaboration with Stratos Genomics

Roche has made strategic investment and entered into a research collaboration agreement with Stratos Genomics, a spin-off of Seattle-based Stratos Group LLC. Both firms are collaborating to support further development of chemistry applied to single molecule sequencing of DNA fragments using protein nanopores. Under this partnership, a focused research team at Roche will work with Stratos scientists to support the development of efficient, low-cost sample preparation methods for DNA Xpandomers and also improve sequencing performance through Roche's expertise in protein design, polymerase mutagenesis, modified nucleotide chemistries and rare reagent manufacturing.

Roche and Ferring Collaborate to Develop Infertility Treatment for Women

Roche has collaborated with Ferring Pharmaceuticals, a research-driven biopharmaceutical company, to combine its diagnostic testing technology with Ferring's human cell line derived recombinant follicle-stimulating hormone, or human rFSH, a gonadotrophin currently in Phase III development, for treatment of infertility in woman. This combination is intended to make it possible for healthcare professionals to personalize infertility treatment to a woman's specific needs. Under the terms of the worldwide agreement, Roche will work with Ferring and its global Phase III programme to qualify, validate, document and seek regulatory approval for a companion diagnostic test to be used in combination with Ferring's human rFSH.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RO:SW SFr.257.50 CHF -0.50

RO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.20 USD -0.12
GlaxoSmithKline PLC 1,564 GBp -8.50
Merck & Co Inc $58.58 USD +0.03
Novartis AG SFr.79.50 CHF -0.15
Sanofi €75.68 EUR -0.02
View Industry Companies
 

Industry Analysis

RO

Industry Average

Valuation RO Industry Range
Price/Earnings 20.6x
Price/Sales 4.6x
Price/Book 11.7x
Price/Cash Flow 16.7x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.